Day 1, April 11

10.00-11.00  Registration

11.00-11.15  Opening Session (Auditorium)
  - 11.00  Karl Einhaeupl, Lesa Mitchell, Stephan Gutzeit: Welcoming Remarks by Co-Chairs

11.15-12.45  Keynote Presentations (Auditorium)
  - 12.00  Anthony J. Atala, Director, Institute for Regenerative Medicine, Wake Forest University, Winston-Salem/ USA: “Regenerative Medicine: Clinical Advances and Models for Clinical Translation.”

12.45-13.45  Networking Luncheon (ground floor)

13.45-15.15  Working Groups Part 1
  - Group A: How to Select, Motivate, and Lead Your Team. (Room 2OG4)
  - Group B: Are European Foundations Doing Enough to Fund Breakthrough Innovations? (Room 2OG2)
  - Group C: Why Collaborations of Universities with Start-up Companies Are Best Suited for Driving Medical Innovations. (Room 2OG1)
  - Group D: How to Find an Incubator that Works for Your Start-up. (Room 2OG3)
  - Group E: Wie man Erfindungen validiert und ihren Wert steigert (in German) (Room EG1)
15.15 Presentations (Auditorium)

- 15.15 Hanson S. Gifford, III, Partner, The Foundry LLC, Menlo Park/ USA: “How to Turn Your Medical Device Concept into a World-Beating Company.”
- 15.45 Nicola Osypka, CEO, OSYPKA AG, Rheinfelden-Herten/ Germany: „How to Build Value with Your Company.”

16.15-16.45 Coffee Break (4th floor)

16.45-18.15 Presentations (Auditorium)

- 16.45 Peter Evans, Senior Advisor, MaRS Discovery District; Managing Partner, Riverdale Partners, Toronto/ Canada: “How to Move an Idea to Income: Marketing and Selling for Technology Entrepreneurs.”
- 17.15 Carl E. Gulbrandsen, Managing Director, Wisconsin Alumni Research Foundation (WARF), Madison/ USA: “The WARF Example: How a Foundation Can Drive Technology Transfer.”
- 17.45 Frank Vogel, Partner, SJ Berwin LLP, Berlin/ Germany: “How to Negotiate a Termsheet with a Venture Capitalist.”

13.30-18.00 Concurrent event for selected inventors & entrepreneurs (by application only) and investors/ business developers:

Module “Charité Partnering”
Track 1: Room 4OG4, Track 2: Room 4OG3

13.30-14.00 Registration for Partnering
14.00-16.00 Track 1: Biotechnology/ Diagnostics & Track 2: Medical Technology
16.00-16.30 Coffee Break
16.30-18.00 One-to-One Meetings

16.30-18.00 Concurrent event for medical researchers, engineers, and entrepreneurs/ MBAs (by application only)

Module “Business Speed Dating” (Room 4OG4)

18.15-19.15 Venture Lounge (by invitation only) (Room 4OG2)

hosted by Peppermint Management GmbH
18.30  **Buses leave for Festive Dinner**

The Gala Dinner takes place at Museum for Communication (Museum für Kommunikation), Leipziger Straße 16, 10117 Berlin, Germany (close to U6 station “Stadtmitte”).

19.00  **Reception**

19.30  **Festive Dinner**

Award Ceremony, German Innovation Award in Medicine (100,000 €) *hosted by Herbert-Worch-Stiftung*

Dinner Speaker:
**Ulf Fink**, CEO, Gesundheitsstadt Berlin e.V.; Founder, WISO Group; former Senator for Health and Welfare; President, Hauptstadtkongress Medizin und Gesundheit, Berlin/ Germany; „Gesundheitsstadt Berlin – Die Bedeutung von Innovationen“ (in German with simultaneous translation).

**Day 2, April 12**

08.00-08.45  **Networking Breakfast** *(4th floor)*

08.45-10.15  **Keynote Presentations** *(Auditorium)*

- **08.45**  **Regis B. Kelly**, Director, California Institute for Quantitative Biosciences (QB3); General Partner, Mission Bay Capital venture fund; former Chair, Bay Area Scientific Innovation Consortium (BASIC), San Francisco/ USA: “The Garage, the Mission Bay Capital Fund, and Bioentrepreneurship at QB3.”

- **9.30**  **Peter Heinrich**, CEO, Magforce Nanotechnologies AG; Co-Founder and former CEO, MediGene AG; President of the Board, B1O Deutschland, Berlin/ Germany: “What Investors Look for: Fundraising and Governance Advice for Technology Entrepreneurs.”

10.15-10.45  **Coffee Break** *(4th floor)*

10.45- 12.15  **Working Groups Part 2**

- **Group A:** Are Super Angels the New Venture Capitalists? *(Room EG1)*
- **Group B:** How to Structure Clinical Trials to Overcome the Latest Regulatory Hurdles in Medtech and Biotech. *(Room 2OG4)*
- **Group C:** Can Entrepreneurship be Learned – And, if so, How? *(Room 2OG2)*
- **Group D:** How Founders Can Form Successful Partnerships with Experienced Serial Entrepreneurs. *(Room 2OG3)*
- **Group E:** How Funders Should Validate Medical Inventions – and Where To Find Funding for Validation Projects. *(Room 2OG1)*
10.45-12.15 Concurrent event for selected researchers, clinicians, industry representatives, and investors:

Module “Unsolved Clinical Problem” (Room 4OG4)

Topic: Radiology

12.15-13.15 Networking Luncheon (4th floor)

13.15-14.45 Working Groups Part 3

- Group A: Disease Foundations and Translational Research: What Are the Lessons Learned so far about Reinventing Drug Development? (Room 2OG2)
- Group B: Market Thinking for Founders: Unmet Medical Needs and How to Address Them. (Room 2OG1)
- Group C: What Founders Should Know when Approaching Venture Capitalists. (Room EG1)
- Group D: The Do's and Don'ts of Collaborating with Big Companies Early. (Room 2OG4)
- Group E: Professor's Privilege vs. University Pre-Emption: The Pros and Cons of Bayh-Dole and the „Arbeitnehmererfindungsgesetz“. (Room 2OG3)

14.45-15.15 Coffee Break (4th floor)

15.15-16.15 Panel Discussion: “How to Structure the Financing of Your Start-up - Venture Capital and Other Options for Founders.” (Auditorium)

- Lesa Mitchell, Vice President, Kauffman Foundation, Kansas City/ USA (Chair)
- Brian Underdown, Managing Director of Technology Investing, Lumira Capital; Member of the Board of Directors, Ontario Genomics Institute; Toronto/ Canada
- Holger Reithinger, Partner, Forbion Capital Partners, Munich/ Germany
- Johannes Schneider-Littfeld, Corporate Vice President, Otto Bock HealthCare GmbH, Duderstadt/ Germany
- Uwe Marx, Co-Founder and former CSO, ProBioGen AG; Project Manager “Multi-Organ-Chips”, TU Berlin, Berlin/ Germany

16.15-17.00 Closing Keynote Presentation (Auditorium)

- 16.15 Peter Thiel, Co-Founder and former CEO, PayPal; Early Investor, Facebook; Founder and Partner, The Founder's Fund; Founder and Benefactor, Thiel Foundation; President, Clarium Capital, San Francisco/ USA: “Developing the Developed World.”

17.00-17.15 Closing Session and Award Ceremony of the “Entrepreneurship Competition” (Auditorium)
17.15  **Medical Entrepreneurship Networking** *(4th floor)*
Sample various kinds of sausages and beer from Germany!

---

19.00-21.00  **Satellite Symposium**  
*hosted by IHK Berlin and Stiftung Charité:*

Podiumsdiskussion: "Charité zwischen globalen Herausforderungen und lokalen Gegebenheiten“ *(in German)* *(Room EG1)*

Panelists:
- Joachim Bovelet, CEO, Vivantes – Netzwerk fuer Gesundheit GmbH
- Karl Max Einhaeupl, CEO, Charité – Universitaetsmedizin Berlin
- Stephan Gutzeit, Executive Director, Stiftung Charité
- Peter Heinrich, President of the Board, BIO Deutschland eV
- Eric Schweitzer, President, IHK Berlin
- Matthias Wernicke, Partner, McKinsey & Co, Inc
Day 1, April 11

Working Groups Part 1 (13.45-15.15)

Group A: How to Select, Motivate, and Lead Your Team. (Room 2OG4)

Chair: Markus Baumanns, Serial Entrepreneur; former CEO, Bucerius Law School; CEO, Schumacher & Baumanns – The Company Companions, Hamburg/ Germany

1. Impulse Speaker: Mariola Soehngen, Co-Founder and Chief Medical Officer, PAION AG, Aachen/ Germany and Cambridge/ UK
2. Impulse Speaker: Martin Goerlitz, Founder and Member of the Executive Board, GOERLITZ Group AG, Koblenz/ Germany
3. Impulse Speaker: Martin Hinoul, Business Development Manager, Leuven Science Park; Charter Member, TiE – The Global Network of Entrepreneurs, Brussels Chapter; Leuven/ Belgium

Group B: Are European Foundations Doing Enough to Fund Breakthrough Innovations? (Room 2OG2)

Chair: Lesa Mitchell, Vice President, Kauffman Foundation, Kansas City/ USA

1. Impulse Speaker: Wilhelm Krull, Secretary General, VolkswagenStiftung, Hannover/ Germany
2. Impulse Speaker: Pier Mario Vello, Secretary General, Fondazione Cariplo, Milan/ Italy
3. Impulse Speaker: Gerrit Rauws, Director, King Baudouin Foundation, Brussels/ Belgium

Group C: Why Collaborations of Universities with Start-up Companies Are Best Suited for Driving Medical Innovations. (Room 2OG1)

Chair: Juergen Meier, Partner, Vossius & Partner, Munich/ Germany

1. Impulse Speaker: Axel Ullrich, Serial Entrepreneur (SUGEN, Axxima Pharmaceuticals, U3 Pharma, Kinaxo) and Director, Max Planck Institute of Biochemistry; Director, Singapore Onco Genome Laboratory; Martinsried/ Germany
2. Impulse Speaker: Jochen Knolle, Director, JCK Life Science Consulting; Co-Founder and former Chief Scientific Officer, Jerini AG, Berlin/ Germany
3. Impulse Speaker: Burton Lee, Managing Director, Innovarium Ventures; Lecturer, Stanford Entrepreneurship Network, Stanford School of Engineering; Palo Alto/ USA
Group D: How to Find an Incubator that Works for Your Start-up.  
(Room 2OG3)

Chair: Jens Fahrenberg, Head of the Innovation Department, Karlsruhe Institute of Technology (KIT), Karlsruhe/ Germany

1. Impulse Speaker: Tim Lenihan, CEO, MD Start (Venture Capital + Accelerator); Founder and CEO, Contract Medical International GmbH, Lausanne/ Switzerland
2. Impulse Speaker: Jens Mundhenke, Unit for Start-up Financing and ESF Coordination, Federal Ministry of Economics and Technology (BMWi), Berlin/ Germany
3. Impulse Speaker: Arne Vesterdal, Director, INCUBA Science Park, Aarhus/ Denmark

Group E: Wie man Erfindungen validiert und ihren Wert steigert (in German).  
(Room EG1)

Chair: Stephan Gutzeit, Executive Director, Stiftung Charité, Berlin/ Germany

1. Impulse Speaker: Joachim Rautter, Managing Partner, Peppermint Venture Partners and Charité Biomedical Fund, Berlin/ Germany
2. Impulse Speaker: Dirk Dantz, CEO, Ipal GmbH, Berlin/ Germany
3. Impulse Speaker: Wilfried Wascher, Head of the Berlin Office and Principal of the Department for Technology Transfer and start-up funding, Project Manager Agency Juelich (Pj), Berlin/ Germany

Day 2, April 12

Working Groups Part 2 (10.45 – 12.15)

Group A: Are Super Angels the New Venture Capitalists? (Room EG1)

Chair: Brigitte Baumann, Founder & CEO, GO BEYOND Early Stage Investing; President, European Business Angel Networks and Seed Funds (EBAN), Zurich/ Switzerland

1. Impulse Speaker: Charles Cameron, Founder and Managing Director, Hub Angels Investment Group LLC; Senior Vice President, Cooley LLP; Member of the Advisory Board, The Capital Network Inc, Boston/ USA
2. Impulse Speaker: Hubertus Leonhardt, Partner, SHS Gesellschaft für Beteiligungmanagement mbH, Tuebingen/ Germany
3. Impulse Speaker: Jochen Noelke, Serial Entrepreneur, Investor, and Business Angel, Hamburg/ Germany
Group B: How to Structure Clinical Trials to Overcome the Latest Regulatory Hurdles in Medtech and Biotech. (Room 2OG4)

Chair: Frank Wagner, Serial Entrepreneur and CEO & CSO, Charité Research Organisation GmbH, Berlin/ Germany

1. Impulse Speaker: Stephanie Krumholz, Global Regulatory Leader, F. Hoffmann-La Roche Ltd., Basel/ Switzerland
2. Impulse Speaker: Marion Jung, Principal, Earlybird Venture Capital, Munich/ Germany

Group C: Can Entrepreneurship be Learned – And, if so, How? (Room 2OG2)

Chair: Barbara Diehl, Programme Manager, Centre for Entrepreneurship and Innovation, Saïd Business School; Member of the Investment Committee, SBS Venture Fund, University of Oxford, Oxford/ UK

1. Impulse Speaker: Pascale Vonmont, Member of the Strategy Board, VENTURE KICK; Deputy Director, Gebert Ruef Stiftung, Basel/ Switzerland
2. Impulse Speaker: Sharon Vosmek, Entrepreneur and Member of the Advisory Board, Illuminate Ventures; CEO, ASTIA (formerly the Women’s Technology Cluster), San Francisco/ USA

Group D: How Founders Can Form Successful Partnerships with Experienced Serial Entrepreneurs. (Room 2OG3)

Chair: Heinz Klandt, Professor for Entrepreneurship, European Business School, Wiesbaden/ Germany

1. Impulse Speaker: John Beadle, CEO, PsiOxus Therapeutics; former Entrepreneur in Residence, Imperial Innovations Group plc, London/ UK
2. Impulse Speaker: Gerald Moeller, Investment Advisor, HBM BioVentures AG, Zug/ Switzerland
3. Impulse Speaker: Timm Jessen, Serial Entrepreneur and former Chief Scientific Officer, Evotec OAI; Managing Director, Scienamics GmbH, Kiel/ Germany

Group E: How Founders Should Validate Medical Inventions – and Where To
Find Funding for Validation Projects (Room 2OG1)
hosted by Herbert-Worch-Stiftung

Chair: Detlev Riesner, Biophysicist and Chairman of the Supervisory Board, QIAGEN N.V.; Member of the Jury, German Innovation Award in Medicine, Herbert-Worch Foundation, Bonn/ Germany

1. Impulse Speaker: Mathias Koelbel, Head of Department, Federal ministry of Education and Research, Berlin/ Germany
2. Impulse Speaker: Guenther Paetz, Chief Financial Officer (CFO), celares GmbH, Berlin/ Germany
3. Impulse Speaker: Ulrich Pison, Professor, Charité – Universitätsmedizin Berlin; CEO, Topass GmbH, Berlin/ Germany

Day 2, April 12

Working Groups Part 3 (13.15 - 14.45)

Group A: Disease Foundations and Translational Research: What Are the Lessons Learned so far about Reinventing Drug Development? (Room 2OG2)

Chair: Adam Zielinski, Deputy Director, Foundation for Polish Science, Warsaw/ Poland

1. Impulse Speaker: Melissa Stevens, Director of Strategic Initiatives, FasterCures, New York/ USA
2. Impulse Speaker: Knut Elbers, Director, Investment Manager of the Boehringer Ingelheim Venture Fund, Boehringer Ingelheim GmbH, Ingelheim/ Germany (invited)
3. Impulse Speaker: Susan Axelrod, Chair, Citizens United for Curing Epilepsy (CURE), Chicago/ USA

Group B: Market Thinking for Founders: Unmet Medical Needs and How to Address Them. (Room 2OG1)

Chair: Karl Naegler, General Partner, Ventech Venture Capital, Paris/ France

1. Impulse Speaker: Paul van Dun, Director, Leuven Development Inc, Catholic University of Leuven, Leuven/ Belgium
2. Impulse Speaker: Brian Horsburgh, Head of Life Sciences, IP Group plc, London/ UK
3. Impulse Speaker: Annegret de Baey-Diepolder, Partner, Gimv Venture Capital, Munich/ Germany
Group C: What Founders Should Know About the European and North American Venture Capital Markets. (Room EG1)

Chair: Klaus Stoeckemann, Managing Partner Charité Biomedical Fund, Peppermint Venture Partners, Berlin/ Germany

1. Impulse Speaker: Valerie Calenda, Partner, Mérieux Développement, Lyon/ France
2. Impulse Speaker: Manfred Ruediger, Serial Entrepreneur; former CEO, t2cure GmbH and Ingeneon AG; Partner, LSP Life Sciences Partners Venture Capital, Munich/ Germany
3. Impulse Speaker: Roman Fleck, Principal, Index Ventures, Geneva/ Switzerland

Group D: The Do's and Don'ts of Collaborating with Big Companies Early. (Room 2OG4)

Chair: Ida Beerhalter, Investment Partner Life Science, BellwaldPartner GmbH, Moehlin/ Switzerland

1. Impulse Speaker: Alexander Schuth, Business Development, Genentech Inc., San Francisco/ USA
2. Impulse Speaker: Wiebke Passmann, Investment Manager, TRIANGLE Venture Capital Group Management GmbH, St. Leon-Rot/ Germany
3. Impulse Speaker: Matthias M. Issing, Principal, Siemens Healthcare Consulting, Siemens AG, Erlangen/ Germany

Group E: Professor's Privilege vs. University Pre-Emption: The Pros and Cons of Bayh-Dole and the “Arbeitnehmererfindungsgesetz”.
(Room 2OG3)

Chair: Martin Mahn, CEO, Humboldt-Innovation GmbH, Berlin/ Germany

1. Impulse Speaker: Lesa Mitchell, Vice President, Kauffman Foundation, Kansas City/ USA
2. Impulse Speaker: Bernhard J. Arnolds, Professor and Director, Center for Technology Transfer, University of Freiburg, Freiburg/ Germany
3. Impulse Speaker: Paolo Milani, Scientific Director, Fondazione Filarete; Director, Interdisciplinary Centre for Nanostructured Materials and Interfaces, University of Milan, Milan/ Italy